Sudarshan Pharma Industries Limited (SPIL) has announced two strategic appointments to bolster its business operations and development teams. The company has brought on board experienced professionals to lead key divisions, signaling a focus on growth and operational excellence.

New Leadership Appointments

Rahul Pandey: Driving Global Healthcare Expertise

Rahul Pandey joins SPIL with over 15 years of experience in the global healthcare industry. His appointment as President of Business Operations & Development for the Excipients & API Division brings valuable expertise to the company. Pandey's background includes:

• Driving growth and operational excellence across APIs, excipients, granules, and specialty ingredients
• Building business presence in key markets including Bangladesh, MENA region, Korea, Indonesia, and China
• Combining global business acumen with deep technical understanding and operational discipline

Pandey's experience with industry leaders such as Pfizer Limited, Mylan Limited, and others positions him well to contribute to SPIL's growth strategies in the pharmaceutical ingredients sector.

Mayank Vyas: Bringing Diverse Industry Experience

Mayank Vyas steps into the role of President - Business Development Manager, bringing over 20 years of experience in marketing and HR across various industries. His diverse background includes:

• Expertise in manufacturing quality and understanding of manufacturing processes
• Experience in problem-solving and quality improvement in manufacturing settings
• Skills in identifying root causes of non-conformity and implementing corrective actions

Vyas's multifaceted experience, spanning construction equipment, tiles, pharma machinery, and chemicals, is expected to bring a fresh perspective to SPIL's business development initiatives.

Corporate Governance and Approval Process

The appointments of both Pandey and Vyas were made following a structured approval process:

1. Initial review and approval by the Nomination Remuneration Committee
2. Final approval by the Board of Directors of Sudarshan Pharma Industries Limited

This process underscores SPIL's commitment to corporate governance and strategic decision-making in its leadership appointments.

The addition of these seasoned professionals to Sudarshan Pharma Industries Limited's leadership team aligns with the company's vision for growth and operational enhancement. As the pharmaceutical industry continues to evolve, the diverse expertise of Pandey and Vyas is expected to play a crucial role in shaping SPIL's future strategies and market position.

Sudarshan Pharma Industries Limited has announced the resignation of Umesh Luthra from his position as Independent Director, effective October 18, 2025. The company disclosed this information in a recent filing.

Resignation Details

Luthra, who holds the Director Identification Number (DIN) 06692755, cited pre-occupation as the reason for his departure. In his resignation letter, he stated that there were no other material reasons for his decision to step down from the board.

Transition Process

The outgoing director has requested the company to complete all necessary formalities related to his resignation. This includes filing the required returns with:

• Stock Exchanges
• Ministry of Corporate Affairs
• Registrar of Companies
• Other relevant authorities

Company's Response

Sudarshan Pharma Industries Limited is expected to proceed with the necessary steps to formalize Luthra's resignation and update their records accordingly.

Impact on Board Composition

The resignation of an Independent Director may have implications for the company's board structure and corporate governance. However, the company has not provided any information regarding a potential replacement or changes to the board composition at this time.

About Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited is engaged in the manufacturing of APIs, jobwork manufacturing in pharmaceuticals items, and trading in chemicals and solvents in India. The company specializes in specialty chemicals.